U.S. CRISPR-Based Gene Editing Market Expansion Driven by Therapeutics

The global U.S. CRISPR-based gene editing market size surpassed USD 941 million in 2024 and is predicted to reach around USD 2,951 million by 2034, registering a CAGR of 12.1% from 2025 to 2034.

Highlights of the U.S. CRISPR-Based Gene Editing Market

• By product, the kits and reagents segment dominated the U.S. CRISPR-based gene editing market in 2024.
• By product, the services segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By gene editing modality, the ex vivo editing segment dominated the market in 2024.
• By gene editing modality, the in vivo editing segment is anticipated to grow at the fastest rate in the CRISPR-based gene editing market during the forecast period.
• By technology, the CRISPR/Cas9 technology segment dominated the market in 2024.
• By technology, the CRISPR/Cas12 technology segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By application, the therapeutic applications segment dominated the market in 2024.
• By application, the agriculture and livestock segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By end-user, the biotechnology and pharmaceutical companies segment dominated the market in 2024.
• By end-user, the agricultural and livestock industry segment is anticipated to grow at the fastest rate in the U.S. CRISPR-based gene editing market during the forecast period.

Industry Valuation and Growth Rate Projection

The U.S. CRISPR-based gene editing market deals with the development of CRISPR-Cas9 technology and its various applications in biotechnology. CRISPR-Cas9 is a breakthrough in gene editing technology, promoting precise and efficient alterations to the DNA of living cells. This innovative tool finds numerous applications across multiple domains, including gene therapy, biomedical research, industrial biotechnology, agriculture, and human reproduction. Within the domain of biomedical research, CRISPR-Cas9 is instrumental in the making of animal models for human disorders. In the context of gene therapy, it permits the correction or insertion of genes in individuals with genetic disorders.

What Are the Market Trends in the U.S. CRISPR-Based Gene Editing Market?

• The market trends in the U.S. CRISPR-based gene editing market show promise, with the market expected to continue its growth with investments from numerous American biotechnology and pharmaceutical giants.
• Biomedical applications, mainly in pharmaceutical and biotechnology firms, are boosting the majority of the market revenue and are anticipated to grow fastest.
• The US government, via institutions such as the NIH, is actively investing in CRISPR-related research, further driving market expansion.
• Continuous innovations in CRISPR systems, like CRISPR/Cas9, CRISPR/Cas12, and base editing technologies, are raising the scope of potential applications.

What Are the Restraints in the U.S. CRISPR-Based Gene Editing Market?

• The growth of the U.S. CRISPR-based gene editing market faces restraints such as the prohibitively high costs of the technology and strict regulations from American regulatory bodies such as the Food and Drug Administration.
• CRISPR-Cas9 technology can still ideal unintended DNA changes at sites other than the intended target, contributing to harmful mutations. This issue is mainly vital in therapeutic applications where edited cells are addressed to patients.
• The FDA and other regulatory bodies need extensive safety data and rigid clinical trials, which can slow down the acceptance process for CRISPR-based therapies.

What Are the Opportunities in the U.S. CRISPR-Based Gene Editing Market?

• Opportunities in the U.S. CRISPR-based gene editing market are plenty, with researchers looking to find oncological treatments, along with other applications in agriculture and genetically modified organisms.
• CRISPR is being examined for cancer research and therapy, including expanding targeted therapies for specific tumor types and improving the effectiveness of existing treatments.
• CRISPR technology is being applied in agriculture to enhance crop yields, improve disease resistance, and generate more nutritious food sources.
• CRISPR permits faster and more efficient drug discovery by permitting researchers to model diseases and test potency therapies in a more targeted way.

Recent Developments in the U.S. CRISPR-Based Gene Editing Market

• In January 2025, Synthego accessed a strategic licensing agreement with AstraZeneca. This agreement helps Synthego obtain a global license to produce and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, currently published as engineered ePsCas9, to the global research community.
• In July 2024, Agilent Technologies Inc. disclosed it had signed a definitive agreement to obtain BIOVECTRA, a leading specialized contract development and producing organization, for $925 million.